CTLA-4 variants

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9884902
APP PUB NO 20150104450A1
SERIAL NO

14399685

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDIMMUNE LIMITEDMILSTEIN BUILDING GRANTA PARK CAMBRIDGE CB21 6GH UNITED KINGDOM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bowen, Michael Gaithersburg, US 46 518
Douthwaite, Julie Cambridge, GB 2 10
Minter, Ralph Cambirdge, GB 24 99
Moisan, Jacques North Potomac, US 3 10
Privezentzev, Cyril Sawston, GB 4 27
Rust, Steven Cambridge, GB 14 62

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 6, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 6, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00